MetaCap

Electra Therapeutics (ETRA) vs 4D Molecular Therapeutics (FDMT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

4D Molecular Therapeutics is the larger company by market cap ($576.8 million vs $509.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ETRA-38.79%FDMT-32.79%
+8%-20%-47%
Sep 18, 20261 yearNov 20, 2026
ETRA-38.79%FDMT-32.79%
+2%-21%-43%
Sep 14, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ETRA versus FDMT key metrics
MetricETRAFDMT
Share price$8.11$10.23
Market cap$509.85M$576.76M
1-day change-9.28%-4.57%
YTD return—+36.40%
1-year return—-5.63%
5-year return—-53.61%
EPS (TTM)$-35.94$-2.70
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$85.21M
Revenue growth (YoY)—+230194.59%
Net income (latest FY)—$-140.11M
Operating margin—-187.24%
Net margin—-164.43%
52-week high$15.50$16.93
52-week low$6.87$6.96
Distance from 52-week high-47.68%-39.57%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+309.37%+174.58%
Average volume559.28K967.00K
Shares outstanding62.87M56.38M
Employees46196
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Electra Therapeutics

ETRA stock →

Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees

About 4D Molecular Therapeutics

FDMT stock →

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 196 employees

ETRA vs FDMT FAQ

Which is bigger, Electra Therapeutics or 4D Molecular Therapeutics?

4D Molecular Therapeutics (FDMT) is larger, with a market capitalization of $576.76M compared with $509.85M for Electra Therapeutics (ETRA).

Are Electra Therapeutics and 4D Molecular Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons